Health Condition 1: F32- Major depressive disorder, singleepisode
Conditions
Interventions
Intervention1: VORTIOXETINE: AFTER RANDOMIZATION AND ALLOCATION CONCEALMENT PATIENT WILL BE GIVEN TAB VORTIOXETINE 10 MG OD
Control Intervention1: VENLAFAXINE: AFTER RANDOMIZATION AND ALLOCATION CONCE
Sponsors
AIIMS PATNA
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients clinically diagnosed as Major Depressive Disorder. 2.Treatment naive patients or who has not taken any treatment since last 1 month 3. Cooperative & willing to participate
Exclusion criteria
Exclusion criteria: 1.Other depressive spectrum disorders (F34- ---) 2.Highly agitated/ suicidal patients/ depression with psychotic symptoms who need immediate treatment 3.ECT in past 6 months 4.Co-morbid axis I psychiatric illness 5.Patients with co-morbid substance abuse except Nicotine use 6.Patients with known history of diabetes mellitus, hypertension or any long standing significant medical illness / significant neurological impairment (cerebrovascular accidents (CVA) / seizure) / clinical observable mental retardation/ History of organicity that precludes participation in study 7.Pregnant and nursing women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CHANGE IN DSST SCORETimepoint: 8 WEEKS | — |
Secondary
| Measure | Time frame |
|---|---|
| change in cognitive scores of individual domainsTimepoint: 8 WEEKS;short-term efficacy and safety of Vortioxetine and Venlafaxine using MADRS, SOFASTimepoint: 8 WEEKS | — |
Countries
India
Contacts
Public ContactCHAYAN KANTI MANNA
AIIMS, PATNA
Outcome results
None listed